- Home
- CLRB vs NCEL Comparison
CLRB vs NCEL Comparison
Compare CLRB & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLRB | NCEL |
|---|---|---|
| Founded | 2002 | 2008 |
| Country | United States | Switzerland |
| Employees | N/A | 11 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9M | 13.2M |
| IPO Year | 2008 | N/A |
Fundamental Metrics
Financial Performance| Metric | CLRB | NCEL |
|---|---|---|
| Price | $2.75 | $2.74 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 28.9K | 15.3K |
| Earning Date | 06-10-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.23 | $1.89 |
| 52 Week High | $10.19 | $4.70 |
Technical Indicators
Market Signals| Indicator | CLRB | NCEL |
|---|---|---|
| Relative Strength Index (RSI) | 41.00 | 48.64 |
| Support Level | $2.55 | $2.63 |
| Resistance Level | $3.60 | $3.19 |
| Average True Range (ATR) | 0.25 | 0.13 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 17.24 | 24.44 |
Price Performance
Historical ComparisonAbout CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
About NCEL NewcelX Ltd. Ordinary Shares
NewcelX Ltd is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. It has research and development operations in Ness Ziona, Israel.